MedTrace Logo

Vvax001 Cancer Vaccine in (Pre) Malignant Cervical Lesions

NCT03141463 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2018-05-03

No results posted yet for this study

Summary

Immune modulating effects and safety of Vvax001; different dosages will be tested in patients with a history of (pre) malignant cervical lesions.

Conditions

Interventions

BIOLOGICAL

Vvax001 therapeutic cancer vaccine

Vvax001 is a vaccine consisting of a replication-incompetent Semliki Forest Virus (SFV) vector encoding HPV-derived tumor antigens. Patients will receive three consecutive doses, with an interval of 3 weeks.

Sponsors & Collaborators

  • Dutch Cancer Society

    collaborator OTHER

  • ViciniVax B.V

    collaborator UNKNOWN

  • University Medical Center Groningen

    lead OTHER

Principal Investigators

  • R Yigit, MD PhD · University Medical Center Groningen

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-13
Primary Completion
2017-11-28
Completion
2017-11-28

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03141463 on ClinicalTrials.gov